Hugel is the leading producer of anti-aging and Botulinum Toxin products in South Korea and Asia.
Croma-Pharma managing director and owner Andreas Prinz noted that the company is always committed to bringing the most advanced anti-aging and medical products to patients and doctors alike.
"With this agreement CROMA-PHARMA will add the most sophisticated Botulinum Toxin products to its well established range of Filler Products sold by the brand-name of Princess. These Princess® Fillers (Rich, Volume and Filler), produced by CROMA-PHARMA itself, are all based on Hyaluronic Acid.
"Intensive research and experience made CROMA-PHARMA the leading European producer and specialist of Hyaluronic Acid-based products. These new Botulinum Toxin-based products will perfectly complement our existing portfolio, meeting the demands of both aesthetic doctors and customers as well," Prinz added.
Croma-Pharma will become the exclusive Distribution Partner and will be responsible for conducting the required clinical trials and studies. CROMA-PHARMA expects to invest an estimated two-digit million Euro amount for conducting these studies.
Following the final approval of FDA, EMA and other authorities, CROMA-PHARMA will then market the new products in Europe, North America and Oceania markets. CROMA-PHARMA will promote the new products under their own brand. Products shall enter the markets in 2018.
Croma-Pharma’s constant search for new trends and product innovations will bring more additions to its well-established product-portfolio in 2014.